New drugs combined to shrink head-neck cancer before surgery
Treatments studied
Part of Cancer clinical trials.
This trial tests two new cancer-fighting drugs (becotatug vedotin and pucotenlimab) given together before surgery to treat head and neck cancer that has come back and stopped responding to previous immunotherapy. The goal is to shrink the tumor enough to make surgery safer and more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have head and neck cancer that has returned or spread after prior immunotherapy and chemotherapy treatment
- Your cancer shows a protein marker (EGFR) on testing and you haven't had EGFR-targeted drugs in the last 6 months
- Your cancer can be surgically removed and has not spread to distant body parts
- You are 18–75 years old and in good enough health to tolerate treatment (ECOG score 0–1)
- Your blood counts, liver function, and kidney function are adequate, checked within the last 7 days
- You are willing to provide a tumor sample for testing or have a fresh biopsy done
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of an immunotherapy drug (adelbelimab) plus chemotherapy given before surgery for head and neck cancer. The goal is to see if this treatment can shrink tumors and improve outcomes for people with advanced but removable head and neck squamous cell carcinoma.
This trial tests a combination of three drugs (becotatug vedotin, pucotenlimab, and cisplatin) given before surgery for head and neck cancer that has not spread far. The goal is to see if this treatment shrinks tumors and improves outcomes for patients with stage 3 or 4A disease.
This trial tests a new drug (antibody-drug conjugate) alone or with an immunotherapy drug before surgery for head and neck cancer that can be removed. The goal is to see if this combination shrinks the tumor and improves outcomes.
This trial tests a new drug combo—becotatug vedotin plus a PD-1 inhibitor—for people with head and neck squamous cell cancer that cannot be surgically removed. It aims to see if this treatment can shrink tumors or slow their growth.
This trial tests a combination of two drugs (pucotenlimab and becotatug vedotin) given before surgery for advanced head and neck squamous cell carcinoma. The goal is to shrink tumors and improve outcomes when combined with surgery.
This trial tests a combination of three drugs (tirelizumab, carboplatin, and a special form of paclitaxel) given before surgery to treat advanced head and neck cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes.
Hear when a new Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.